Holen Sie sich die Stockscreener-App
91.79
0.46%
-0.42
Vorhandelsmarkt:
91.36
-0.43
-0.47%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$92.21
Offen:
$92.275
24-Stunden-Volumen:
3.20M
Relative Volume:
0.63
Marktkapitalisierung:
$52.85B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
49.87
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-3.56%
1M Leistung:
+7.85%
6M Leistung:
+9.48%
1J Leistung:
+17.60%
1-Tages-Spanne:
$91.50
$93.09
1-Wochen-Bereich:
$90.69
$96.29
52-Wochen-Spanne:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
91.79 | 52.85B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
92.11 | 160.44B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
331.45 | 127.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.57 | 106.97B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.65 | 66.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update - Moomoo
Edwards Lifesciences to pay record $10m for HSR evasion - Global Competition Review
Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance - MLex
RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating - marketscreener.com
Edwards Lifesciences stock reflects steady growth prospects in cardiovascular care - ad-hoc-news.de
Edwards Lifesciences stands out as US agency eyes broader access for heart valve device - MSN
Edwards Lifesciences CVP sells $56,762 in company stock - Investing.com UK
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Form 4 Edwards Lifesciences Corp For: 10 July By Investing.com - Investing.com India
Edwards Lifesciences CVP sells $56,762 in company stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CFO receives stock, performance unit and option grants - Stock Titan
Edwards Lifesciences (NYSE: EW) CVP exercises stock options and sells 619 shares - Stock Titan
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System - GlobeNewswire Inc.
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth - ad-hoc-news.de
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus - Kalkine Media
Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - ad-hoc-news.de
The Edwards SAPIEN 3 Ultra ValvePrecision Transcatheter Option For US Heart Patients - AD HOC NEWS
Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com South Africa
Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity - Investing.com
Edwards Lifesciences (EW) executive has shares withheld for tax on vesting - Stock Titan
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp - ad-hoc-news.de
Edwards Lifesciences Investors Seek 1st OK For $39M Deal - Law360
EWEdwards Lifesciences Corp Latest SEC Filings - Finviz
EW Maintained by Evercore ISI Group -- Price Target Raised to $1 - GuruFocus
Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector - DirectorsTalk Interviews
Edwards Lifesciences stock leans on its core heart valve business - ad-hoc-news.de
Law firm investigates Edwards Lifesciences offi... - Pluang
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? - marketscreener.com
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com - Investing.com Nigeria
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick - Investing.com
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at 92.94 USD - Investing.com
What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - Yahoo Finance
Edwards Lifesciences highlights heart valve portfolio as investors watch long-term growth - AD HOC NEWS
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com Nigeria
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com - Investing.com Canada
TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock - Investing.com
Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan - Stock Titan
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences (EW) Gains FDA Approval for Ecliptis System - GuruFocus
Edwards Lifesciences Wins FDA Clearance for ECLIPTIS LAA System - Medical Device and Diagnostic industry
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):